Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 3Cognitive Dysfunction 2Tobacco Use Disorder 1Rectal Neoplasms 1Prostatic Neoplasms 1Neurotoxicity Syndromes 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Lung Neoplasms 1Ependymoma 1Craniopharyngioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 5Vincristine 3Oxaliplatin 3Mental Status and Dementia Tests 3Magnetic Resonance Spectroscopy 3Carboplatin 3Amifostine 3xaliproden 2glucarpidase 2Taxes 2Radiotherapy 2Psychiatric Rehabilitation 2Procarbazine 2Methotrexate 2Magnesium Sulfate 2Leucovorin 2Doxorubicin 2Cyclophosphamide 2Cisplatin 2Calcium Gluconate 22,2'-dithiodiethanesulfonic acid 2neurotropin 1glutamic acid diethyl ester 1eribulin 1axicabtagene ciloleucel 1Vitamin E 1Trastuzumab 1Thioctic Acid 1Thalidomide 1Tadalafil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neurotoxicity Syndromes × Memantine × Clear all
NCT00566852 2017-08-21

Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

Radiation Therapy Oncology Group

Phase 3 Completed
554 enrolled 12 charts
CNS

Brain Neoplasms, Neoplasm Metastasis, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡